RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ProQR Therapeutics Stock

ProQR Therapeutics Net Income 2024

ProQR Therapeutics Net Income

-32.88 M EUR

Ticker

PRQR

ISIN

NL0010872495

WKN

A12B97

In 2024, ProQR Therapeutics's profit amounted to -32.88 M EUR, a 16.92% increase from the -28.12 M EUR profit recorded in the previous year.

The ProQR Therapeutics Net Income history

YEARNET INCOME (undefined EUR)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-

ProQR Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into ProQR Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by ProQR Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects ProQR Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of ProQR Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into ProQR Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing ProQR Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on ProQR Therapeutics’s growth potential.

ProQR Therapeutics Revenue, EBIT and net profit per share

DateProQR Therapeutics RevenueProQR Therapeutics EBITProQR Therapeutics Net Income
2029e29.62 M undefined0 undefined0 undefined
2028e48.1 M undefined-18.64 M undefined0 undefined
2027e8.1 M undefined-50.65 M undefined0 undefined
2026e15.61 M undefined-50.04 M undefined-57.53 M undefined
2025e23.93 M undefined-36.92 M undefined-49.46 M undefined
2024e26.74 M undefined-35.81 M undefined-32.88 M undefined
20239.53 M undefined-31.86 M undefined-28.12 M undefined
20224.8 M undefined-64.72 M undefined-65.11 M undefined
20212.4 M undefined-57.19 M undefined-61.62 M undefined
20209.45 M undefined-42.37 M undefined-46.57 M undefined
20191.93 M undefined-57.45 M undefined-56.48 M undefined
20185.76 M undefined-36.29 M undefined-36.89 M undefined
20171.5 M undefined-40.5 M undefined-43.64 M undefined
20161.83 M undefined-39.57 M undefined-39.1 M undefined
20153.24 M undefined-27 M undefined-20.83 M undefined
2014310,000 undefined-16.46 M undefined-12.13 M undefined
2013120,000 undefined-3.24 M undefined-3.25 M undefined
201220,000 undefined-420,000 undefined-420,000 undefined

ProQR Therapeutics stock margins

The ProQR Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of ProQR Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for ProQR Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the ProQR Therapeutics's sales revenue. A higher gross margin percentage indicates that the ProQR Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the ProQR Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the ProQR Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the ProQR Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the ProQR Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the ProQR Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

ProQR Therapeutics Margin History

ProQR Therapeutics Gross marginProQR Therapeutics Profit marginProQR Therapeutics EBIT marginProQR Therapeutics Profit margin
2029e0 %0 %0 %
2028e0 %-38.76 %0 %
2027e0 %-625.5 %0 %
2026e0 %-320.62 %-368.57 %
2025e0 %-154.27 %-206.64 %
2024e0 %-133.9 %-122.94 %
20230 %-334.48 %-295.21 %
20220 %-1,348.33 %-1,356.46 %
20210 %-2,382.92 %-2,567.5 %
20200 %-448.36 %-492.8 %
20190 %-2,976.68 %-2,926.43 %
20180 %-630.03 %-640.45 %
20170 %-2,700 %-2,909.33 %
20160 %-2,162.3 %-2,136.61 %
20150 %-833.33 %-642.9 %
20140 %-5,309.68 %-3,912.9 %
20130 %-2,700 %-2,708.33 %
20120 %-2,100 %-2,100 %

ProQR Therapeutics Aktienanalyse

What does ProQR Therapeutics do?

ProQR Therapeutics NV is a Dutch biotechnology company focused on the production of RNA medications for the treatment of genetic diseases. The company was founded in 2012 by Daniel de Boer, Dinko Valerio, and Gerard Platenburg. Since its IPO in 2014, the company has been listed on the NASDAQ. ProQR utilizes a technology called RNA therapeutics, which consists of RNA and offers an alternative treatment method, especially for genetic diseases. Thanks to RNA medications, it is possible to repair faulty mRNA sequences and correct gene expression. This can help fight diseases caused by defective genes, including previously considered incurable diseases. The company works closely with researchers and doctors to develop innovative therapies that truly help patients. Their focus is on diseases that have not been treatable or have a low cure rate in conventional medicine. Diseases that ProQR deals with include cystic fibrosis, inherited retinal diseases, inherited amyloidosis, cancer treatment, and rare genetic diseases. Cystic fibrosis, also known as CF, is one of the most well-known diseases that the company treats. This disease mainly affects children and young adults. Cystic fibrosis is caused by a mutation of the CFTR gene, which disrupts the salt-water balance in the lungs and pancreas. ProQR has developed an RNA therapy called QR-010, which aims to repair the function of the CFTR gene and alleviate the lungs and pancreas. ProQR works closely with clinics to treat patients with this therapy. The company also has RNA medications in the pipeline that help with inherited retinal diseases. One of these diseases is retinitis pigmentosa, which kills the retina and can lead to blindness. ProQR is developing a drug called QR-421a, which is intended to improve vision. The company hopes that the drug will soon be on the market and help patients with retinitis pigmentosa. ProQR is also working on the development of RNA medications to combat rare genetic diseases. This includes the treatment of amyloidosis, a disease in which abnormal proteins accumulate in the body and cause damage. RNA medications could help interrupt the production of abnormal proteins, thereby minimizing damage in the body. ProQR is also working on RNA therapy for cancer. The company focuses on developing medications to combat genetically caused cancer, particularly tumors caused by the loss of heterozygosity (LOH). These tumors can be treated with RNA medications targeting correct gene expression. ProQR Therapeutics NV has had an impressive success story in recent years. The company holds several patents on RNA therapeutics and has built an excellent reputation as a biotechnology company. ProQR's RNA therapies have the potential to successfully treat many genetic diseases that are not possible with conventional medicine. They represent a source of hope for many patients, especially those with cystic fibrosis. The company will continue to develop new RNA therapeutics to treat rare genetic diseases that have been difficult to fight. ProQR Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding ProQR Therapeutics's Profit Margins

The profit margins of ProQR Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of ProQR Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating ProQR Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

ProQR Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When ProQR Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about ProQR Therapeutics stock

How much profit has ProQR Therapeutics made this year?

ProQR Therapeutics has made -32.88 M EUR this year.

How has the profit developed compared to last year?

The profit has increased by 16.92% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does ProQR Therapeutics publish its earnings?

ProQR Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of ProQR Therapeutics?

The profits of ProQR Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of ProQR Therapeutics?

You can learn more about the earnings of ProQR Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does ProQR Therapeutics pay?

Over the past 12 months, ProQR Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ProQR Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of ProQR Therapeutics?

The current dividend yield of ProQR Therapeutics is .

When does ProQR Therapeutics pay dividends?

ProQR Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ProQR Therapeutics?

ProQR Therapeutics paid dividends every year for the past 0 years.

What is the dividend of ProQR Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is ProQR Therapeutics located?

ProQR Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von ProQR Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ProQR Therapeutics from 11/5/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did ProQR Therapeutics pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of ProQR Therapeutics in the year 2023?

In the year 2023, ProQR Therapeutics distributed 0 EUR as dividends.

In which currency does ProQR Therapeutics pay out the dividend?

The dividends of ProQR Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von ProQR Therapeutics

Our stock analysis for ProQR Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ProQR Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.